Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase

被引：396

作者：

Guagnano, Vito ^{[1
]}

Furet, Pascal ^{[1
]}

Spanka, Carsten ^{[1
]}

Bordas, Vincent ^{[1
]}

Le Douget, Mickael ^{[1
]}

Stamm, Christelle ^{[1
]}

Brueggen, Josef ^{[1
]}

Jensen, Michael R. ^{[1
]}

Schnell, Christian ^{[1
]}

Schmid, Herbert ^{[1
]}

Wartmann, Markus ^{[1
]}

Berghausen, Joerg ^{[1
]}

Drueckes, Peter ^{[1
]}

Zimmerlin, Alfred ^{[1
]}

Bussiere, Dirksen ^{[1
]}

Murray, Jeremy ^{[1
]}

Porta, Diana Graus ^{[1
]}

机构：

[1] Novartis Inst BioMed Res, CH-4002 Basel, Switzerland

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2011年 / 54卷 / 20期

关键词：

HUMAN BREAST; MULTIPLE-MYELOMA; MYELOPROLIFERATIVE SYNDROME; ONCOGENE AMPLIFICATION; ACTIVATING MUTATIONS; GENE AMPLIFICATION; FGF FAMILY; INT-2; GENE; EXPRESSION; CANCER;

D O I：

10.1021/jm2006222

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A novel series of N-aryl-N'-pyrimidin-4-yl ureas has been optimized to afford potent and selective inhibitors of the fibroblast growth factor receptor tyrosine kinases 1, 2, and 3 by rationally designing the substitution pattern of the aryl ring. On the basis of its in vitro profile, compound 1h (NVP-BGJ398) was selected for in vivo evaluation and showed significant antitumor activity in RT112 bladder cancer xenografts models overexpressing wild-type FGFR3. These results support the potential therapeutic use of 1h as a new anticancer agent.

引用

页码：7066 / 7083

页数：18

共 61 条

[41]

Regenass U., 1995, Indolocarbazole alkaloid derivatives for sensitizing multidrug-resistant cells to antitumor agents, Patent No. 9532975

[42] FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas [J].

Reis-Filho, Jorge Sergio ;

Simpson, Pete T. ;

Turner, Nicholas C. ;

Lambros, Maryou Ballo ;

Jones, Chris ;

Mackay, Alan ;

Grigoriadis, Anita ;

Sarrio, David ;

Savage, Kay ;

Dexter, Tim ;

Iravani, Marjan ;

Fenwick, Kerry ;

Weber, Barbara ;

Hardisson, David ;

Schmitt, Fernando Carlos ;

Palacios, Jose ;

Lakhani, Sunil R. ;

Ashworth, Alan .

CLINICAL CANCER RESEARCH, 2006, 12 (22) :6652-6662

[43] Design, Structure-Activity Relationships and in Vivo Characterization of 4-Amino-3-benzimidazol-2-ylhydroquinolin-2-ones: A Novel Class of Receptor Tyrosine Kinase Inhibitors [J].

Renhowe, Paul A. ;

Pecchi, Sabina ;

Shafer, Cynthia M. ;

Machajewski, Timothy D. ;

Jazan, Elisa M. ;

Taylor, Clarke ;

Antonios-McCrea, William ;

McBride, Christopher M. ;

Frazier, Kelly ;

Wiesmann, Marion ;

Lapointe, Gena R. ;

Feucht, Paul H. ;

Warne, Robert L. ;

Heise, Carla C. ;

Menezes, Daniel ;

Aardalen, Kimberly ;

Ye, Helen ;

He, Molly ;

Le, Vincent ;

Vora, Jayesh ;

Jansen, Johanna M. ;

Wernette-Hammond, Mary Ellen ;

Harris, Alex L. .

JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (02) :278-292

[44] A novel chromosomal translocation t(4;14)(p16.3;q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene [J].

Richelda, R ;

Ronchetti, D ;

Baldini, L ;

Cro, L ;

Viggiano, L ;

Marzella, R ;

Rocchi, M ;

Otsuki, T ;

Lombardi, L ;

Maiolo, AT ;

Neri, A .

BLOOD, 1997, 90 (10) :4062-4070

[45] Design, Synthesis, and Evaluation of Indolinones as Triple Angiokinase Inhibitors and the Discovery of a Highly Specific 6-Methoxycarbonyl-Substituted Indolinone (BIBF 1120) [J].

Roth, Gerald J. ;

Heckel, Armin ;

Colbatzky, Florian ;

Handschuh, Sandra ;

Kley, Joerg ;

Lehmann-Lintz, Thorsten ;

Lotz, Ralf ;

Tontsch-Grunt, Ulrike ;

Walter, Rainer ;

Hilberg, Frank .

JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (14) :4466-4480

[46] Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations [J].

Roumiantsev, S ;

Krause, DS ;

Neumann, CA ;

Dimitri, CA ;

Asiedu, F ;

Cross, NCP ;

Van Etten, RA .

CANCER CELL, 2004, 5 (03) :287-298

[47] AMPLIFICATION OF THE INT-2 GENE IN HEAD AND NECK SQUAMOUS-CELL CARCINOMA [J].

RUBIN, JS ;

QIU, L ;

ETKIND, P .

JOURNAL OF LARYNGOLOGY AND OTOLOGY, 1995, 109 (01) :72-76

[48]

Seki A, 2000, INT J ONCOL, V17, P103

[49] Identification of four new translocations involving FGFRI in myeloid disorders [J].

Sohal, J ;

Chase, A ;

Mould, S ;

Corcoran, M ;

Oscier, D ;

Iqbal, S ;

Parker, S ;

Welborn, J ;

Harris, RI ;

Martinelli, G ;

Montefusco, V ;

Sinclair, P ;

Wilkins, BS ;

van den Berg, H ;

Vanstraelen, D ;

Goldman, JM ;

Cross, NCP .

GENES CHROMOSOMES & CANCER, 2001, 32 (02) :155-163

[50] Design, synthesis, and evaluations of substituted 3-[(3-or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases [J].

Sun, L ;

Tran, N ;

Liang, CX ;

Tang, F ;

Rice, A ;

Schreck, R ;

Waltz, K ;

Shawver, LK ;

McMahon, G ;

Tang, C .

JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (25) :5120-5130

← 1 2 3 4 5 6 7 →